| Name | Title | Contact Details |
|---|
CARBONDALE CLINIC AND SURGERY is a Carbondale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NanoCellect`s mission is to facilitate biomedical breakthroughs by making cell analysis and sorting technology more affordable and easier to use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF`s technology before launching the WOLF (our first product) in 2016. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts and recently backed by FusionX Ventures and other private investors.
At Lexington Regional Health Center, we are redefining health care. By embracing a truly patient-centered care model, we focus on you and your family`s needs. From urgent care and 24-hour emergency services, to radiology and physical therapy, we are here for you. Walking through our doors, you`ll feel right at home, because you are. Between detection and prevention, therapy and recovery, diagnosis and treatment; in the middle of it all, Lexington Regional is your health center.
Chiropractors Buying Group is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.